The calls to ensure the impact of Brexit on patient safety is “as limited as possible” came as the Committee published its report following an inquiry into ‘Brexit: medicines, medical devices and substances of human origin’. The report urges all parties to consider the needs of industry and patient groups and to ensure close regulatory alignment between the UK and the EU.
The Committee’s key recommendations include:
Dr Sarah Wollaston MP says in the report: “In order to minimise harm to their citizens, both the UK and the EU27 should look to secure the closest possible regulatory alignment in the next round of the Brexit negotiation.”
The report included written and oral evidence from the HDA on priority issues for its members. HDA chief executive Martin Sawer is quoted as stressing the importance of the medicines supply chain, saying: “Quite rightly, we take the supply chain for granted. A doctor writes a prescription; the patient might go into a pharmacy in the morning and the pharmacy says, ‘Come back in the afternoon and the medicine will be there’.
“We are invisible, and we should be, but I think it is important to recognise that the supply chain is there and operating all the time. A jolt to it like this could throw a lot of cogs out of a very complicated machine.”